SCHEMBL14714958

SCHEMBL14714958

O=C(NC(C(=O)NO)C(=O)NCCc1ccccn1)c1ccc(-c2ccc(OCCO)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
NPC1 O15118 2/20 0.52
KMT2A Q03164 3/20 0.50
ALDH1A1 P00352 3/20 0.50
MEN1 O00255 2/20 0.50
HPGD P15428 1/20 0.46
HSD17B10 Q99714 1/20 0.46
MMP1 P03956 1/20 0.46
MMP3 P08254 1/20 0.46
LMNA P02545 1/20 0.43
POLB P06746 1/20 0.43
HTT P42858 1/20 0.42
ATM Q13315 1/20 0.42
MAPK14 Q16539 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14715017 0.90 HPGD (0.55) RAB9ASMN1; SMN2NPC1KMT2AALDH1A1
SCHEMBL14714750 0.86 MEN1 (0.57) RAB9ASMN1; SMN2NPC1KMT2AMEN1
SCHEMBL14715199 0.85 NPC1 (0.51) RAB9ASMN1; SMN2NPC1KMT2AALDH1A1
SCHEMBL14714981 0.85 ANPEP (0.49) NPC1MMP1MMP3
SCHEMBL14714742 0.83 NPC1 (0.49) RAB9ASMN1; SMN2NPC1KMT2AMEN1
SCHEMBL14715049 0.82 PPARG (0.51) MMP1MMP3
SCHEMBL14714497 0.82 PPARG (0.51) RAB9ASMN1; SMN2NPC1MMP1
SCHEMBL14714895 0.82 PPARG (0.46) RAB9ANPC1KMT2AMEN1MMP1
SCHEMBL14714574 0.81 PPARG (0.46) NPC1ALDH1A1LMNA
SCHEMBL14714713 0.81 USP2 (0.46) NPC1HSD17B10MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2562155-B1 HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO LTD (JP) 2019-06-05 EP disclosed
US-9499477-B2 Hydroxamic acid derivative TOYAMA CHEMICAL CO., LTD. (JP) 2016-11-22 US disclosed
US-9499477-B2 Hydroxamic acid derivative TOYAMA CHEMICAL CO., LTD. (JP) 2016-11-22 US disclosed
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2015-08-13 US disclosed
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2015-08-13 US disclosed
US-9073821-B2 Hydroxamic acid derivative TAISHO PHARMACEUTICAL CO., LTD (JP) 2015-07-07 US disclosed
US-9073821-B2 Hydroxamic acid derivative TAISHO PHARMACEUTICAL CO., LTD (JP) 2015-07-07 US disclosed
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TOYAMA CHEMICAL CO., LTD. (JP) 2013-03-21 US disclosed
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TOYAMA CHEMICAL CO., LTD. (JP) 2013-03-21 US disclosed
EP-2562155-A1 NOVEL HYDROXAMIC ACID DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-02-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE LCT, AGXT, HDAC9 RAB9A 2523/4885SMN1; SMN2 4755/4885NPC1 3272/4885
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE LCT, AGXT, HDAC9 RAB9A 2523/4885SMN1; SMN2 4755/4885NPC1 3272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.